糖尿病是一类病因及发病机制复杂的内分泌代谢性疾病,发病率逐年升高。监测血糖可以调整饮食、运动、药物等治疗,从而,达到最佳的血糖控制,减少糖尿病的并发症,提高糖尿病患者的生存质量。糖化血红蛋白(glycosylated hemoglobin;GHB)的常规临床试验检测首先在二十世纪70年代晚期开始应用。GHB做为反映平均血糖的指数,及与糖尿病并发症发展程度的相关危险性指标,在临床中,被广泛用来 Diabetes mellitus is a type of endocrine and metabolic diseases with complicated etiology and pathogenesis, and its incidence is increasing year by year. Monitoring blood glucose can be adjusted diet, exercise, medication and other treatments, so as to achieve the best blood sugar control, reduce the complications of diabetes and improve the quality of life of patients with diabetes. Routine clinical trial testing of glycosylated hemoglobin (GHB) first began in the late 1970s. GHB as an index to reflect the average blood glucose, and diabetic complications associated with the degree of development of risk indicators in clinical practice, is widely used